Search: (WFRF:(Torgeirsson Hlin)) >
Inhibition of dipep...
-
Ahrén, BoLund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
(author)
Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.
- Article/chapterEnglish2002
Publisher, publication year, extent ...
-
American Diabetes Association,2002
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-211308
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-211308URI
-
https://lup.lub.lu.se/record/107861URI
-
https://doi.org/10.2337/diacare.25.5.869DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
OBJECTIVE: Glucagon-like peptide-1 (GLP-1) has been proposed as a new treatment modality for type 2 diabetes. To circumvent the drawback of the short half-life of GLP-1, inhibitors of the GLP-1-degrading enzyme dipeptidyl peptidase IV (DPP IV) have been examined. Such inhibitors improve glucose tolerance in insulin-resistant rats and mice. In this study, we examined the 4-week effect of 1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine (NVP DPP728), a selective, orally active inhibitor of DPP IV, in subjects with diet-controlled type 2 diabetes in a placebo-controlled double-blind multicenter study.RESEARCH DESIGN AND METHODS: A total of 93 patients (61 men and 32 women), aged 64 +/- 9 years (means +/- SD) and with BMI 27.3 +/- 2.7 kg/m(2), entered the study. Fasting blood glucose was 8.5 +/- 1.5 mmol/l, and HbA(1c) was 7.4 +/- 0.7%. Before and after treatment with NVP DPP728 at 100 mg x 3 (n = 31) or 150 mg x 5 (n = 32) or placebo (n = 30), subjects underwent a 24-h study with standardized meals (total 2,000 kcal).RESULTS: Compared with placebo, NVP DPP728 at 100 mg t.i.d. reduced fasting glucose by 1.0 mmol/l (mean), prandial glucose excursions by 1.2 mmol/l, and mean 24-h glucose levels by 1.0 mmol/l (all P < 0.001). Similar reductions were seen in the 150-mg b.i.d. treatment group. Mean 24-h insulin was reduced by 26 pmol/l in both groups (P = 0.017 and P = 0.023). Although not an efficacy parameter foreseen in the study protocol, HbA(1c) was reduced to 6.9 +/- 0.7% in the combined active treatment groups (P < 0.001). Laboratory safety and tolerability was good in all groups.CONCLUSIONS: We conclude that inhibition of DPP IV is a feasible approach to the treatment of type 2 diabetes in the early stage of the disease.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Simonsson, Erik
(author)
-
Larsson, Hillevi
(author)
-
Landin-Olsson, MonaLund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)med-mla
(author)
-
Torgeirsson, Hlin
(author)
-
Jansson, Per-Anders
(author)
-
Sandqvist, Madeléne
(author)
-
Båvenholm, Peter
(author)
-
Efendic, Suad
(author)
-
Eriksson, Jan WUppsala universitet,Endokrin diabetes och metabolism
(author)
-
Dickinson, Sheila
(author)
-
Holmes, David
(author)
-
Medicin, LundSektion II
(creator_code:org_t)
Related titles
-
In:Diabetes Care: American Diabetes Association25:5, s. 869-750149-59921935-5548
Internet link
Find in a library
To the university's database
- By the author/editor
-
Ahrén, Bo
-
Simonsson, Erik
-
Larsson, Hillevi
-
Landin-Olsson, M ...
-
Torgeirsson, Hli ...
-
Jansson, Per-And ...
-
show more...
-
Sandqvist, Madel ...
-
Båvenholm, Peter
-
Efendic, Suad
-
Eriksson, Jan W
-
Dickinson, Sheil ...
-
Holmes, David
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Endocrinology an ...
- Articles in the publication
-
Diabetes Care
- By the university
-
Uppsala University
-
Lund University